This study explores the cost–effectiveness of reduced doses or discontinuation of etanercept biosimilar (Yisaipu) in patients with moderately active rheumatoid arthritis (RA). PubMed, Clin Exp Rheumatol, 12/01/2014. (Also see: Treatments for Rheumatoid Arthritis and Biologic Agents.)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.